EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety Profile of Nebulized Ciprofloxacin‐Dexamethasone After Pediatric Airway Surgery

Abbey L Landini iD, Cyrus W Abrahamson iD, Maya Frost, David Spielberg, Inbal Hazkani, Dana M Thompson, Jonathan B Ida, Sarah Maurrasse iD, Taher Valika iD

The Laryngoscope · 2026

DOI: 10.1002/lary.70643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Laryngoscope, 2026. Verfasst von Abbey L Landini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Dexamethasone, Ciprofloxacin, Postoperative Complications. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the safety profile and patterns of use of nebulized ciprofloxacin–dexamethasone (CPD) in pediatric patients undergoing airway surgery.

Methods

A retrospective chart review was performed of patients who underwent airway surgery at a tertiary pediatric center between 2019 and 2023 and received nebulized CPD 0.3%–0.1% postoperatively. Demographic, clinical, and procedural data were extracted. Exposure was defined as any postoperative nebulized administration. Adverse events were considered potentially CPD‐related if they occurred during administration or within 30 days of discontinuation without a better explanation. Outcomes included endocrine, metabolic, infectious, pulmonary, and inflammatory complications.

Results

A total of 399 patients received nebulized CPD. Mean age was 46.2 months (range: newborn–20.7 years). Indications included subglottic stenosis (92.5%), post‐laryngotracheal reconstruction (5.3%), airway foreign body (2.0%), and supraglottoplasty (0.3%). Comorbidities were frequent, including neurologic conditions (47.6%), cardiac anomalies (41.6%), and bronchopulmonary dysplasia (25.1%). Most patients (93.4%) received CPD in the inpatient setting, for a mean duration of 11.7 days. No cases of adrenal suppression, glucose abnormalities, or bronchial hyperreactivity were identified. One patient had suspected airway fungal infection while receiving chemotherapy, though pathology was negative. Among the 85.7% of patients who underwent postoperative endoscopic evaluation, no significant inflammatory findings were observed.

Conclusion

Nebulized CPD Was Uniformly Incorporated Into Postoperative Airway Management in This Large Pediatric Cohort and Well Tolerated, With no Significant Adverse Events Observed. These Findings Support the Safety of CPD in Medically Complex Children and Highlight the Need for Multicenter Prospective Studies to Evaluate Efficacy and Optimize Dosing Protocols. Level of Evidence 3

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneCiprofloxacinPostoperative ComplicationsHumansFemaleRetrospective StudiesInfantChild, PreschoolMaleChildNebulizers and VaporizersAdolescentInfant, NewbornAdministration, InhalationPostoperative Care

Stichwörter der Autor:innen

adverse eventsciprofloxacin‐dexamethasonenebulized therapypediatric airway surgerysafetysubglottic stenosis

Substanzen

DexamethasoneCiprofloxacin

Autor:innen und Institutionen

  • Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Department of Pediatrics-Pulmonology, Baylor University, Texas Children's Hospital, Houston, Texas, USA.
  • Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
  • Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Department of Surgery, Division of Otolaryngology, Yale University, New Haven, Connecticut, USA.

ORCID-Profile: Abbey L Landini, Cyrus W Abrahamson, Sarah Maurrasse, Taher Valika

Zitieren

APA

Landini, A. L., Abrahamson, C. W., Frost, M., Spielberg, D., Hazkani, I., Thompson, D. M., Ida, J. B., Maurrasse, S., & Valika, T. (2026). Safety Profile of Nebulized Ciprofloxacin‐Dexamethasone After Pediatric Airway Surgery. The Laryngoscope. https://doi.org/10.1002/lary.70643

Vancouver

Landini AL, Abrahamson CW, Frost M, Spielberg D, Hazkani I, Thompson DM, et al. Safety Profile of Nebulized Ciprofloxacin‐Dexamethasone After Pediatric Airway Surgery. The Laryngoscope. 2026. doi:10.1002/lary.70643

BibTeX
@article{Landini2026,
  author = {Landini, Abbey L and Abrahamson, Cyrus W and Frost, Maya and Spielberg, David and Hazkani, Inbal and Thompson, Dana M and Ida, Jonathan B and Maurrasse, Sarah and Valika, Taher},
  title = {Safety Profile of Nebulized Ciprofloxacin‐Dexamethasone After Pediatric Airway Surgery},
  journal = {The Laryngoscope},
  year = {2026},
  doi = {10.1002/lary.70643}
}
Kostenlos starten →